Should Statin Be Started in Patients with CAD?
Yes, statin therapy must be initiated in all patients with coronary artery disease (CAD) unless contraindicated—this is a Class I, Level A recommendation that reduces major cardiovascular events, mortality, and improves quality of life. 1
Core Recommendation
High-intensity statin therapy is first-line treatment for all patients with established CAD, targeting an LDL-C goal of <1.4 mmol/L (55 mg/dL) with at least a 50% reduction from baseline. 1
High-intensity statins (atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily) reduce LDL-C by 45-50% on average and should be initiated before hospital discharge in newly diagnosed CAD patients. 1
Statin therapy reduces major vascular events by 22%, all-cause mortality by 10%, and coronary heart disease mortality by 20% per 1.0 mmol/L reduction in LDL-C. 1
Treatment Strategy
Initial Approach
Start with high-intensity statin therapy immediately upon CAD diagnosis, ideally during the index hospitalization. 1
Early in-hospital statin prescription (before discharge) significantly improves long-term compliance (77% vs 40%) and reduces mortality (5.7% vs 11.7%). 2
For patients who cannot tolerate high-intensity statins, a treat-to-target strategy using moderate-intensity statins titrated to LDL-C 50-70 mg/dL is noninferior for preventing death, myocardial infarction, stroke, or revascularization. 3
Combination Therapy When Needed
Most patients require combination lipid-lowering therapy to achieve guideline-recommended LDL-C targets—statin monotherapy alone is insufficient in many cases. 1
Add ezetimibe as second-line therapy when LDL-C goals are not met with maximally tolerated statin therapy, providing an additional 20-25% LDL-C reduction. 1
For very high-risk patients (those experiencing a second vascular event within 2 years while on maximum statin therapy), consider an even lower LDL-C goal of <1.0 mmol/L (40 mg/dL). 1
PCSK9 inhibitors (alirocumab or evolocumab) lower LDL-C by 60% when added to statins and significantly reduce non-fatal cardiovascular events, though without impact on cardiovascular mortality. 1
Important Caveats
Contraindications
Statins must not be given when pregnancy is planned, during pregnancy, or during breastfeeding. 1
Avoid in patients with documented adverse effects or true statin intolerance. 1
Special Considerations
For patients with triglycerides ≥200 mg/dL, treat with statins to lower non-HDL-C to <130 mg/dL. 1
If triglycerides >500 mg/dL, add fibrate therapy to prevent acute pancreatitis. 1
In patients with statin intolerance, use bile acid sequestrants and/or niacin as alternative LDL-C-lowering therapy. 1
Clinical Reality Check
Only 20% of CAD patients on statins achieve guideline-recommended LDL-C targets in real-world practice, highlighting the critical need for aggressive combination therapy and close monitoring. 4 The treatment gap between indicated therapy and actual prescription remains significant, making early in-hospital initiation essential for long-term success. 2
The evidence is unequivocal: statin therapy initiated early after CAD diagnosis decreases fatal events and improves survival, with the greatest benefit seen when treatment begins during the index hospitalization rather than being deferred to outpatient follow-up. 5, 2